10 Most Profitable Growth Stocks to Buy
On May 26, Michael Dehal, Senior Portfolio Manager at Dehal Investment Partners of Raymond James Ltd., appeared on BNN Bloomberg to discuss the outlook for the markets.
Ascendis Pharma A/S (ASND)
This company is not actively trading or the ticker does belong to another company in our database now. The symbol (ASND) is currently associated with the following stock: Ascendis Pharma A/S (ASND)
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 10,281,496 | $2,351,686,580 | 24.92% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 5,062,500 | $1,157,945,625 | -1% | 11.39% |
| 3. | Perceptive Advisors Joseph Edelman | 1,531,421 | $350,281,925 | +42% | 6.84% |
| 4. | Polar Capital Brian Ashford-Russell And Tim Woolley | 651,712 | $149,066,086 | +76% | 0.53% |
| 5. | Vestal Point Capital Ryan Wilder | 375,000 | $85,773,750 | +115% | 2.4% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,813,440 | $1,100,978,089 | 4.62% | |
| 2. | 3,876,601 | $886,694,943 | 0.05% | |
| 3. | 3,230,188 | $738,840,836 | 1.19% | |
| 4. | 2,051,948 | $469,341,976 | 0.11% | |
| 5. | 1,958,843 | $448,046,159 | 0.11% |
News See All
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the First Quarter Ascendis Pharma Earnings Conference Call.
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
Joseph Edelman, the billionaire chief of New York-based Perceptive Advisors, specializes in the biotechnology and life sciences sectors.
7 Best Strong Buy European Stocks to Invest In
European stocks are getting a closer look as investors search beyond the crowded parts of the U.S.
7 Fastest Growing European Stocks to Invest In
European stocks are getting a closer look again, and not only because investors want to diversify away from a crowded U.S. trade.
Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth
Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years.
10 Best NASDAQ Growth Stocks to Buy for the Next 2 Years
On February 19, Tom Lee of Fundstrat and BitMine joined 'Closing Bell' on CNBC to talk about the state of the markets.
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2025 Earnings Call Transcript
Operator: At this time, participants are in listen-only mode. Thank you for standing by, and welcome to the Ascendis Pharma A/S Fourth Quarter 2025 Earnings Conference Call.
RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets
Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best high growth European stocks to buy.
BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT
In other news, on January 20, TheFly reported that Wells Fargo analyst Derek Archila upgraded the price target on Ascendis Pharma from $322 to $330, keeping an Overweight rating on the stock.
Hedge Fund Resource Center